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Abstract
Background:  Inadequate serum vitamin D [25(OH)D] concentrations are associated with
secondary hyperparathyroidism, increased bone turnover and bone loss, which increase fracture
risk. The objective of this study is to assess the prevalence of inadequate serum 25(OH)D
concentrations in postmenopausal Belgian women. Opinions with regard to the definition of
vitamin D deficiency and adequate vitamin D status vary widely and there are no clear international
agreements on what constitute adequate concentrations of vitamin D.
Methods:  Assessment of 25-hydroxyvitamin D [25(OH)D] and parathyroid hormone was
performed in 1195 Belgian postmenopausal women aged over 50 years. Main analysis has been
performed in the whole study population and according to the previous use of vitamin D and
calcium supplements. Four cut-offs of 25(OH)D inadequacy were fixed : < 80 nmol/L, <75 nmol/L,
< 50 nmol/L and < 30 nmol/L.
Results: Mean (SD) age of the patients was 76.9 (7.5) years, body mass index was 25.7 (4.5) kg/
m2. Concentrations of 25(OH)D were 52.5 (21.4) nmol/L. In the whole study population, the
prevalence of 25(OH)D inadequacy was 91.3 %, 87.5 %, 43.1 % and 15.9% when considering cut-
offs of 80, 75, 50 and 30 nmol/L, respectively. Women who used vitamin D supplements, alone or
combined with calcium supplements, had higher concentrations of 25(OH)D than non-users.
Significant inverse correlations were found between age/serum PTH and serum 25(OH)D (r = -
0.23/r = -0.31) and also between age/serum PTH and femoral neck BMD (r = -0.29/r = -0.15). There
is a significant positive relation between age and PTH (r = 0.16), serum 25(OH)D and femoral neck
BMD (r = 0.07). (P < 0.05)
Vitamin D concentrations varied with the season of sampling but did not reach statistical
significance (P = 0.09).
Conclusion:  This study points out a high prevalence of vitamin D inadequacy in Belgian
postmenopausal osteoporotic women, even among subjects receiving vitamin D supplements.
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Background
Osteoporosis is a chronic, progressive disease character-
ized by reduced bone mass and microarchitectural deteri-
oration of bone, involving an extensive fragility and a
subsequent increase in fracture risk [1].
Vitamin D and calcium are essential components of oste-
oporosis management. Once vitamin D is absorbed from
the diet or synthetised in the skin by the action of sun-
light, it is metabolized first in liver to 25-hydroxyvitamin
D [25(OH)D] and then in kidney to 1,25-dihydroxyvita-
min D [1,25(OH)2D], before becoming biologically
active. Then, 1,25(OH)2D interacts with its nuclear recep-
tor (VDR) in target tissues where appropriate biological
responses are mediated, in particular to maintain calcium
homeostasis by increasing efficiency of intestinal calcium
absorption [2]. As a consequence, decreasing 25(OH)D
serum concentrations leads to reduced calcium absorptive
performance yielding to an increase in PTH concentra-
tions [3]. This leads to an increased bone resorption and
accelerated bone loss, by increasing the number and activ-
ity of osteoclasts that release calcium from bone. Decreas-
ing bone mineral density (BMD) and bone strength with
increased susceptibility to fragility-fracture risk are ulti-
mate consequences of vitamin D deprivation [4-6]. Vita-
min D inadequacy has also been implicated as a
contributing factor to muscle weakness and propensity to
fall, both in active and inactive ambulatory elderly sub-
jects [7,8]. A positive relationship has also been shown
between cognitive functioning and vitamin D concentra-
tions, which may also influence the risk of fall and frac-
ture [9].
Sunlight and diet are the two sources of vitamin D. UV-B
irradiation is the primary source of vitamin D. Approxi-
mately 90% of serum vitamin D is produced endog-
enously from 7-dehydrocholesterol in the epidermis of
the skin, after adequate exposure. However, the capacity
of the skin to produce vitamin D declines with aging
[4,10,11]. Moreover, environmental factors influence the
cutaneous production of vitamin D. Latitude, season, and
time of day as well as ozone pollution in the atmosphere
diversify the number of solar ultraviolet B photons reach-
ing the earth's surface, and thereby, alter the cutaneous
production of vitamin D3 [12].
As a consequence, in the light of the implication of vita-
min D deficiency in bone metabolism, osteoporosis pre-
vention guidelines developed by scientific authorities
contain recommendations for vitamin D intake and evi-
dence-based treatment of osteoporosis requires vitamin D
supplements to maintain adequate plasma concentration
[13-15].
The objective of this study is to assess the prevalence of
inadequate serum vitamin D concentrations in postmen-
opausal Belgian women.
Methods
Belgian postmenopausal women aged over 50 years were
included in the study (n = 1195), of which overall 52.5 %
had a prior fragility fracture. These women were part of a
run-in study aimed at normalizing the calcium and vita-
min D status of patients prior to be included in a trial,
investigating the anti-fracture efficacy of a new anti-oste-
oporotic drug. Women were eligible for this study if they
had been postmenopausal for at least five years, with at
least one fracture confirmed by spinal radiography or a
lumbar-spine bone mineral density (BMD) ≤ 0.840 g/cm2
or a femoral neck BMD ≤ 0.600 g/cm2. Among the women
included in this study, 26.4% already received vitamin D
supplements (vitamin D3) and 45.4% got calcium sup-
plementation.
After receiving information from the investigator, and
being able to ask questions regarding all aspects of the
study, all participants provided written informed consent
before enrolment; the study was approved by the Institu-
tional Review Board of the University of Liège, BELGIUM.
Fasting blood and urine samples were collected at base-
line, stored at -80°C and centrally analyzed. Assessment
of 25-hydroxyvitamin D [25(OH)D] was performed with
a commercial radioimmunoassay [DiaSorin (formerly
Incstar Corporation), Stillwater, Minnesota, USA]. It con-
sists of a two-step procedure. In a first step, the 25(OH)D
and other hydroxylated metabolites are rapidly extracted
from serum or plasma with acetonitrile. The extract is then
assayed by RIA using a polyclonal antibody with specifi-
city to 25(OH)D. The sample, the antibody and the tracer
are incubated for 90 minutes at room temperature (20–
25°C). The complexes «antigen-antibody» are separated
after 20 minutes incubation at RT with a second antibody
precipitating complex. This radioimmunoassay is a com-
petitive binding assay with a limit of detection of 4 ng/ml
and a within and between assay precision lower than 8%.
In this particular study, four cut-offs of 25(OH)D inade-
quacy were fixed : < 80 nmol/L (mild deficiency), <75
nmol/L (moderate deficiency), < 50 nmol/L (severe defi-
ciency) and < 30 nmol/L (very severe deficiency). The lab-
oratory performing the 25(OH)D assessment take part in
a 25(OH)D quality scheme such as the International
Quality Assessment Scheme for Vitamin D metabolites
(DEQAS).
The assay of the intact PTH (hPTH 1–84) was performed
with the "N-tact(R) PTH SP IRMA Kit" from DiaSorin.
Bone mineral density at the lumbar spine and proximalBMC Public Health 2007, 7:64 http://www.biomedcentral.com/1471-2458/7/64
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femur was measured by dual-energy x-ray absorptiometry.
The BMD of the two proximal femurs were assessed and
the lowest femoral neck BMD was reported. A spine phan-
tom was scanned each morning as a quality control and
for instrument calibration.
Statistical analysis
The primary analysis has been performed in the whole
study population and in three different categories of age
(50–69 years, 70–79 years and 80 years and more). We
also performed analysis according to the previous use of
vitamin D supplements and we stratified our analysis
according to the type of supplementation: patients with-
out supplementation (group 1, n = 637), patients receiv-
ing calcium alone (group 2, n = 241), patients with
vitamin D but without calcium supplements (group 3, n
= 14), patients with calcium and vitamin D supplements
(group 4, n = 302).
Analyses have been stratified according to sunlight expo-
sure. In Belgium (50 degrees latitude North), spring is
defined as March through June, summer as June through
September, fall as September through December and win-
ter as December though March.
Normality of variables has been confirmed by Kol-
mogorov-Smirnov tests. Student T tests were used to com-
pare mean values of serum 25(OH)D in women with and
without vitamin D supplement. ANOVA was performed
to compare mean values of serum 25(OH)D and PTH
according to the four groups of supplementation, age
groups and seasons. Pairwise comparisons with adjust-
ment for multiple comparisons (Bonferroni) were also
made if the ANOVA was significant. Correlation coeffi-
cients were calculated to assess the relationship between
the variables. All the data were analyzed using STATIS-
TICA (version7.1; StatSoft Inc). P-values < 0.05 were
regarded as significant.
Results
The 1195 women included in this study were aged (mean
+/- SD) 76.9 ± 7.5 years. Their mean [SD] serum concen-
trations of 25(OH)D, calcium, PTH were 52.5 (21.4)
nmol/L, 2,37 (0.12) mmol/L and 31.2 (14.9) pg/mL,
respectively. The characteristics of the study population
are presented in Table 1.
In the whole study population, the lowest serum
25(OH)D concentrations (<30 nmol/L) were observed in
15.9 % of all women. When considering the 50 and 80
nmol/L cut-offs, the prevalence reaches 43.1% and
91.3%, respectively.
The mean [SD] serum 25(OH)D concentrations reached
63 (20) nmol/L in women with vitamin D supplements
compared to 48.7 (20.7) nmol/L in women without vita-
min D supplements (P < 0.001).
When stratified according to calcium and vitamin D sup-
plementation, women who used vitamin D supplements,
only or combined with calcium supplements, had higher
concentrations of 25(OH)D than non-users : 59.3 nmol/
L (group 3) and 63.1 nmol/L (group 4) vs 45.9 nmol/L
(group 1) and 56.4 nmol/L (group 2) (P < 0.001). The
groups 1, 2 and 4 differ statistically with each other (Bon-
ferroni correction – P < 0.001).
In groups receiving vitamin D supplements, severe
25(OH)D inadequacy (<50 nmol/L) was reported in
28.6% of the women. Mild and moderate inadequacy was
reported by 85.7% and 82.8% of the women, respectively.
In absence of vitamin D supplementations, 55.3 % of the
patients presented severe inadequacy and 96.2% mild
inadequacy (Figure 1).
There was a significant negative correlation between age
and serum 25(OH)D (r = -0.23; P  < 0.05). The mean
serum 25(OH)D concentrations were 57.9 nmol/L in
women aged less than 70 years old (n = 137). When con-
sidering patients aged more than 80 years (n = 430),
25(OH)D concentrations were 45.7 nmol/L. In the inter-
mediate group (n = 628), the mean concentrations of
25(OH)D were 56 nmol/L. The vitamin D inadequacy
was significantly higher in the oldest age group (57.2 %
and 93.7 % when considering cut-offs of 50 and 80 nmol/
L, respectively) compared with the youngest age groups
(32.8 % and 57.6 %) (P < 0.001). The youngest age groups
differed statistically from the oldest age group (Bonferroni
correction – P < 0.001). (Figure 2)
A significant negative correlation was also found between
serum 25(OH)D and PTH (r = -0.31; P < 0.05; figure 3),
serum PTH rising with age (r = 0.16;P < 0.05). In figure 4,
comparing the effects of 25(OH)D concentrations and age
on PTH, patients were grouped according to their age cat-
egory and then further grouped, according to their
25(OH)D concentrations. For all age categories, there was
a substantial and progressive decrease of PTH concentra-
tion as 25(OH)D increased. The lowest serum PTH con-
centrations were observed in the groups with serum 25-
hydroxyvitamin D concentrations of more than 80 nmol/
L, whereas the highest serum PTH was observed in the
groups with serum 25(OH)D concentrations lower than
50 nmol/L. The PTH concentrations of the oldest group
(80 years and more) were consistently higher than those
of younger subjects. These differences are based on signif-
icant ANOVA and Bonferroni tests (P < 0.001). Further-
more, mean PTH concentrations were statistically
different in each category of 25(OH)D concentrations
(Bonferroni test – P < 0.05)BMC Public Health 2007, 7:64 http://www.biomedcentral.com/1471-2458/7/64
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When stratified according to calcium and vitamin D sup-
plementation, women who used vitamin D supplements,
only or combined with calcium supplements, had lower
PTH concentrations than non-users: 31.2 pg/mL (group
3) and 26.6 pg/mL (group 4) vs 34.2 pg/mL (group 1) and
30.2 nmol/L (group 2) (P < 0.001); although not reaching
statistical significance after Bonferroni correction,
between group 3 and the three other groups (P < 0.05).
A significant negative correlation between age, serum PTH
and femoral neck BMD was found in the studied popula-
tion (r = -0.29 and -0.15; P < 0.05). We found also too a
positive correlation between serum 25(OH)D and femo-
ral neck BMD (r = 0.07; P < 0.05). Whereas no correlation
between these variables (age, serum 25(OH)D and serum
PTH) and BMD at lumbar spine was observed.
25(OH)D concentration did not vary with the season of
sampling. Spring (March 20 – June 21) was characterized
by lower concentrations of 25(OH)D (50.9 nmol/L),
while higher concentrations were observed in summer
(June 21-September 23) (55.1 nmol/L). The prevalence of
vitamin D severe inadequacy (50 nmol/L cut-off) during
spring, summer, autumn and winter was 45.3%, 39.1%,
44.5 % and 43 %, respectively. However, these values did
not reach statistical significance (P = 0.09). (Table 2)
Table 1: Baseline characteristics of the 1195 Belgian postmenopausal women.
Mean ± SD Range
Age (years) 76.9 ± 7.5 50 – 100
Body mass index (kg/m2) 25.7 ± 4.5 13.6 – 44.3
Lumbar bone mineral density (g/cm2) 0.767 ± 0.13 0.387 – 1.357
Femoral neck bone mineral density (g/cm2) 0.522 ± 0.08 0.211 – 0.953
Serum 25-hydroxyvitamin D (nmol/L) 52,5 ± 21.4 12.5 – 175
Serum Calcium (mmol/L) 2,37 ± 0.12 1.93 – 2.85
Serum intact parathyroid hormone (pg/mL) 31,2 ± 14.9 6 – 174.6
Percentage of subjects having serum 25(OH)D concentration below various thresholds in the different groups stratified  according to their type of supplementation Figure 1
Percentage of subjects having serum 25(OH)D concentration below various thresholds in the different groups stratified 
according to their type of supplementation.BMC Public Health 2007, 7:64 http://www.biomedcentral.com/1471-2458/7/64
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Discussion
The results of this study show a high prevalence of vitamin
D inadequacy amongst Belgian postmenopausal women,
irrespective of the threshold used for the diagnosis.
The serum concentrations of 25(OH)D are most valuable
for determining the overall vitamin D status of an individ-
ual, since it is an average of dietary and sunlight-induced
vitamin D. The measurement of the serum 1,25(OH)2D
concentrations has been most useful in evaluating disor-
ders in calcium and bone metabolism related to acquired
and inborn errors in the conversion of 25(OH)D to
1,25(OH)2D [16-18].
Assessment of 25-hydroxyvitamin D [25(OH)D] was per-
formed with a commercial radioimmunoassay (Dia-
Sorin). It is important to specify that interlaboratory
variability in serum 25-hydroxyvitamin D (25(OH)D)
results is often reported because of the use of different
methodologies (protein binding, chemiluminescent and
RIA assays). This variation in measurement confounds the
diagnosis of vitamin D insufficiency. Consequently, these
assays must be internationally standardized and made
available to practicing clinicians [19]. From this perspec-
tive, the International Quality Assessment Scheme for
Vitamin D metabolites (DEQAS) was introduced in 1989
to improve the reliability of 25-hydroxyvitamin D (25-
OHD) assays [20].
No universal consensus has been reached regarding serum
values constitutive of inadequacy. Indeed, the vitamin D
status that fully normalizes calcium absorption is not
known for humans [3]. Recent publications suggest that
the circulating concentration of 25(OH)D should be over
80 nmol/L or at least between 50 nmol/L and 80 nmol/L
to optimize intestinal calcium absorption, minimize
increased parathyroid activity and reduce the risk of hip
and other non vertebral fractures [21,22]. It has been
demonstrated that calcium absorption is reduced in
patients with 25(OH)D concentrations below 80 nmol/L
corresponding to higher PTH secretion (reported at
25(OH)D values below 80 nmol/L) [3]. In this particular
study, two cut-offs of 25(OH)D inadequacy were fixed : <
80 nmol/L and < 50 nmol/L. However, we also used the
threshold of 75 nmol/l, suggested by a consensus expert
panel and a review [22,23] and a concentration of 30
nmol/L, considered by certain authors as the lower limit
indicating a severe deficiency [24-27].
Various studies found that postmenopausal women who
have osteoporosis (involving low bone mineral density
and/or history of fragility fracture) are more likely to have
serum vitamin D concentrations below the normal range.
For example, in United Kingdom, in 330 patients with fra-
gility fractures from Glasgow, Belfast and Medway, mean
concentrations of 25(OH)D ranged from 40 nmol/L to
52.3 nmol/L and 83.7 to 96.4 % of patients had 25-
hydroxyvitamin D concentrations < 80 nmol/L and 55.8
to 73.2 % < 50 nmol/L. 694 patients with hip fractures
were specially identified from Belfast, Glasgow and Lon-
don. Their mean concentrations of 25(OH)D ranged from
24.7 nmol/L to 36.1 nmol/L and 81.6 to 92.7 % had a
concentration < 50 nmol/L [28]. In a systematic review of
30 publications reporting prevalence estimates for vita-
min D inadequacy in populations with osteoporosis asso-
ciated with other disorders possibly, the prevalence of
25(OH)D concentrations < 12 ng/mL (30 nmol/L) ranged
from 12.5 % to 76 %, while prevalence rates reached 50 %
to 70 % of patients with a history of fracture(s) using a
cut-off of 15 ng/mL [29].
However, the prevalence observed in our cohort of oste-
oporotic postmenopausal women is generally lower than
previously reported in elderly subjects in previous studies
and in healthy adults [30]. The women enrolled in our
study were fairly healthy, free of diseases other than oste-
oporosis. In addition, volunteers for clinical trials may be
more conscious about their health than the general popu-
lation. All these factors may have contributed to the lower
overall prevalence of vitamin D deficiency observed in
this study compared with previous studies. Same observa-
tions have been reported in two recent studies. In a multi-
national study of 18 countries, the mean serum 25(OH)D
concentrations of 2606 osteoporotic postmenopausal
women were 26.8 ng/mL (67 nmol/L) with an average
serum 25(OH)D of 29.3 ng/mL (73.2 nmol/L) in Europe.
Overall, 64 % of patients had serum concentrations < 30
ng/mL (75 nmol/L) and women receiving pharmacologi-
cal treatment for osteoporosis had mean concentrations
similar to those recorded in women who were not receiv-
ing such treatment [31]. In the Multiple Outcomes of
Raloxifene Evaluation study, a large prospective interven-
tion trial in postmenopausal women with osteoporosis,
Effect of age on prevalence of vitamin D inadequacy Figure 2
Effect of age on prevalence of vitamin D inadequacy.BMC Public Health 2007, 7:64 http://www.biomedcentral.com/1471-2458/7/64
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the mean serum 25(OH)D concentrations of the whole
study population (n = 7564) were 70.8 nmol/L (65.9
nmol/L in Central Europe). Low serum 25(OH)D (<50
nmol/L) were observed in 39 % of the women living in
Central Europe [32].
We also show that the prevalence of vitamin D inade-
quacy remains major, even amongst subjects receiving
vitamin D supplements, with or without calcium. One
could wonder if the supplementations are really appropri-
ate to the individual needs in postmenopausal oste-
oporotic women although we have no data on the doses
and length of supplementation used and the compliance
of the subjects.
In our cohort, we observe a significant correlation
between age and vitamin D [25(OH)D] concentrations.
These results seem to be in accordance with previous stud-
ies, showing a highest prevalence of vitamin D deficiency
in the oldest population varying from 5–25% in inde-
pendent elderly to 60–80% in institutionalized elderly
[32,33]. It has been shown that there is an age-dependent
decrease in the epidermal concentrations of provitamin
D3 (7-dehydrocholesterol) that explains the growing
incapacity of human skin to produce vitamin D3 [10]. In
elderly, kidneys are less effective to hydroxylate vitamin D
to form 1,25-dihydroxyvitamin D (1,25(OH)2D3) [34].
Furthermore, there is a defect in intestinal absorption of
cholecalciferol in the elderly, after oral ingestion [35]. In
Adjusted mean serum parathyroid hormone values according  to serum 25-hydroxyvitamin D values and age group Figure 4
Adjusted mean serum parathyroid hormone values according 
to serum 25-hydroxyvitamin D values and age group.
Plot of serum intact PTH concentrations versus serum 25(OH)D concentrations Figure 3
Plot of serum intact PTH concentrations versus serum 25(OH)D concentrations.BMC Public Health 2007, 7:64 http://www.biomedcentral.com/1471-2458/7/64
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the same way, a late age-related decrease in calcium
absorption is seen in postmenopausal women, in addi-
tion to the decline that occurs at menopause. This
decrease could be due to a decline in either the active cal-
cium transport or diffusion component of the calcium
absorption system [36]. Moreover, in elderly, a depletion
of body vitamin D stores results from a lack of sun expo-
sure, due to progressive disability with age and subse-
quent the tendency to stay indoors, low dietary intake and
reduced ability to adapt to a low calcium diet. This con-
tributes to a higher prevalence of vitamin D inadequacy
[34,37].
The combined deficiency in calcium and vitamin D, wide-
spread in the ageing population, stimulates the secretion
of parathyroid hormone which tends to normalize serum
calcium concentrations, contributes to accelerated bone
loss and plays a central role in pathogenesis of bone dis-
orders and osteoporosis in the elderly [38]. Concomi-
tantly, a decrease in bone strength and loss of muscle mass
occurs.
Consistent with other reports, we find an inverse correla-
tion between 25(OH)D and PTH, and a PTH rise with age
[32,39,40]. In addition, 25(OH)D concentrations were
positively correlated with hip BMD, similar to other stud-
ies of Caucasian postmenopausal women. The negative
correlation of PTH concentrations with femoral neck
BMD is also in accordance with other studies. [33,39,41-
43]
In our study, we also show a difference in vitamin D
[25(OH)D] concentrations between seasons, the lowest
concentrations being seen during the spring months and
the highest during the summer months. However, this dif-
ference is not statistically significant. These findings are in
accordance with previous studies, especially with a similar
study done in another European country [44]. In our
study, it should be pointed that vitamin D inadequacy is
high (over 89 % with the 80 nmol/L cut-off) even during
summer. These results suggest that vitamin D supplement
may be requested in osteoporotic postmenopausal
women, independently of the season.
Many studies have demonstrated the effectiveness of cal-
cium and vitamin D supplementation in fracture preven-
tion particularly in patients with appropriate adherence to
treatment. However, effectiveness of vitamin D alone in
fracture prevention is still debated [45-52]. Calcium and
vitamin D have been shown to reverse secondary hyper-
parathyroidism with resulting beneficial effects on bone
mineral density (BMD)[37]. Additionally, it has been
shown that calcium and vitamin D supplementation sig-
nificantly improve body sway, muscle function and lower
extremity strength, as well as reduce the risk of falls [53-
55].
There is general agreement that adequate vitamin D and
calcium intake is the cornerstone of osteoporosis preven-
tion. In patients with documented osteoporosis, calcium
and vitamin D supplementation should be a first line
component of the osteoporosis care, along with antire-
sorptive or anabolic treatment [53].
Conclusion
This study points out a high prevalence of vitamin D inad-
equacy in Belgian postmenopausal osteoporotic women
even among subjects receiving vitamin D supplements.
More studies are needed to address the amount of vitamin
D intake necessary to maintain serum 25(OH)D to an
adequate concentration which prevents secondary hyper-
parathyroidism and minimizes the possibility of further
bone loss.
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